OMERS ADMINISTRATION Corp Invests $378,000 in Genmab A/S (NASDAQ:GMAB)

OMERS ADMINISTRATION Corp purchased a new stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 18,100 shares of the company's stock, valued at approximately $378,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Deep Track Capital LP bought a new stake in Genmab A/S during the 4th quarter worth approximately $41,740,000. Renaissance Technologies LLC increased its stake in shares of Genmab A/S by 7.8% in the fourth quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company's stock valued at $40,199,000 after buying an additional 139,722 shares in the last quarter. First Trust Advisors LP increased its stake in shares of Genmab A/S by 18.0% in the fourth quarter. First Trust Advisors LP now owns 1,644,288 shares of the company's stock valued at $34,316,000 after buying an additional 251,241 shares in the last quarter. Brandywine Global Investment Management LLC bought a new position in shares of Genmab A/S in the fourth quarter valued at about $33,804,000. Finally, Marshall Wace LLP lifted its position in Genmab A/S by 162.2% during the 4th quarter. Marshall Wace LLP now owns 1,122,296 shares of the company's stock worth $23,422,000 after buying an additional 694,243 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GMAB has been the subject of several research reports. Truist Financial lowered their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a research report on Thursday, February 13th. HC Wainwright reiterated a "buy" rating and issued a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Finally, William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $39.17.

Genmab A/S Stock Up 1.5%

Shares of Genmab A/S stock opened at $20.18 on Tuesday. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $30.06. The business has a fifty day simple moving average of $19.74 and a 200 day simple moving average of $20.73. The stock has a market cap of $12.94 billion, a PE ratio of 11.60, a price-to-earnings-growth ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The company had revenue of $715.00 million during the quarter, compared to analysts' expectations of $5.17 billion. Analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.